Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report)’s stock price fell 24.7% during mid-day trading on Monday . The company traded as low as $1.13 and last traded at $1.13. 2,300 shares changed hands during trading, an increase of 82% from the average session volume of 1,267 shares. The stock had previously closed at $1.50.
Silence Therapeutics Stock Performance
The stock has a 50 day simple moving average of $1.49 and a 200 day simple moving average of $3.33.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
See Also
- Five stocks we like better than Silence Therapeutics
- Insider Trading – What You Need to Know
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- 3 Monster Growth Stocks to Buy Now
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- What Investors Need to Know to Beat the Market
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
